RxDoctor Payments Data

Dave Ringer, MD

Family Medicine · Greensboro, GANPI 1992784433

Payments from drug & device makers

$1,106in general payments, 2019–2025

Across 20 payments — averaging $55.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$302
  • AstraZeneca$158
  • Edwards Lifesciences$150
  • Mylan Specialty L.p.$147
  • Xeris Pharmaceuticals, Inc.$74
  • Teva Pharmaceuticals USA, Inc.$57
  • plus $218 from 5 others

What the payments were for

  • Food & beverage$1,106100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,106 in reported general payments places this provider in the 60th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$12,699
Medicare patients
140
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,386$222,298
TrulicityDulaglutide110$56,899
JardianceEmpagliflozin289$49,938
XareltoRivaroxaban304$44,959
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$40,562
Rosuvastatin Calcium4,486$32,380
OzempicSemaglutide29$29,365
Invega SustennaPaliperidone Palmitate11$27,502
Risperdal ConstaRisperidone Microspheres33$27,466
Potassium Chloride2,520$26,897
Lantus SolostarInsulin Glargine,hum.Rec.Anlog658$26,538
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog46$26,205
TradjentaLinagliptin173$23,150
JanuviaSitagliptin Phosphate142$20,847
Amlodipine Besylate3,437$20,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invega Sustenna, Risperdal Consta$50$99,927348 claims
AstraZenecaLokelma$158$11,31037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Greensboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →